Advertisement

 

 

CDK9 inhibitors in acute myeloid leukemia.

CDK9 inhibitors in acute myeloid leukemia.
Author Information (click to view)

Boffo S, Damato A, Alfano L, Giordano A,


Boffo S, Damato A, Alfano L, Giordano A, (click to view)

Boffo S, Damato A, Alfano L, Giordano A,

Advertisement

Journal of experimental & clinical cancer research : CR 2018 02 2337(1) 36 doi 10.1186/s13046-018-0704-8

Abstract

Current treatment for acute myeloid leukemia (AML) is less than optimal, but increased understanding of disease pathobiology and genomics has led to clinical investigation of novel targeted therapies and rational combinations. Targeting the cyclin-dependent kinase 9 (CDK9) pathway, which is dysregulated in AML, is an attractive approach. Inhibition of CDK9 leads to downregulation of cell survival genes regulated by super enhancers such as MCL-1, MYC, and cyclin D1. As CDK9 inhibitors are nonselective, predictive biomarkers that may help identify patients most likely to respond to CDK9 inhibitors are now being utilized, with the goal of improving efficacy and safety.

Submit a Comment

Your email address will not be published. Required fields are marked *

five + 12 =

[ HIDE/SHOW ]